| 15.02 -0.46 (-2.97%) | 09-14 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 19.87 |
1-year : | 21.4 |
| Resists | First : | 17.01 |
Second : | 18.32 |
| Pivot price | 16.65 |
|||
| Supports | First : | 14.89 |
Second : | 12.38 |
| MAs | MA(5) : | 15.7 |
MA(20) : | 16.75 |
| MA(100) : | 15.43 |
MA(250) : | 16.2 |
|
| MACD | MACD : | -0.2 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 2.5 |
D(3) : | 3 |
| RSI | RSI(14): 39.5 |
|||
| 52-week | High : | 21.5 | Low : | 13.05 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ MESO ] has closed above bottom band by 0.2%. Bollinger Bands are 13.6% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 15.27 - 15.42 | 15.42 - 15.5 |
| Low: | 14.58 - 14.77 | 14.77 - 14.89 |
| Close: | 14.8 - 15.11 | 15.11 - 15.3 |
Mesoblast Limited is a biopharmaceutical firm dedicated to the development and commercialization of allogeneic cell-based therapies. Its global presence extends across the United States, Australia, Singapore, the United Kingdom, and Switzerland. The company addresses a broad spectrum of medical conditions, including cardiovascular, spinal orthopedic disorders, oncology, hematology, and immune-mediated and inflammatory diseases. At the core of its innovation is a proprietary regenerative medicine platform utilizing specialized mesenchymal lineage cells. Currently, several of Mesoblast's leading product candidates are undergoing Phase III clinical trials: remestemcel-L, designed for severe, steroid-refractory acute graft versus host disease and acute respiratory distress syndrome associated with COVID-19; Rexlemestrocel-L, aimed at advanced chronic heart failure; and MPC-06-ID, intended for chronic low back pain stemming from degenerative disc disease. Additionally, MPC-300-IV is being developed for biologic-refractory rheumatoid arthritis and diabetic nephropathy. The company has cultivated strategic partnerships to advance its pipeline and market reach. These collaborations include Tasly Pharmaceutical Group for the distribution of MPC-150-IM (heart failure) and MPC-25-IC (heart attacks) in China; JCR Pharmaceuticals Co. Ltd. for therapies addressing wound healing in patients with epidermolysis bullosa; and Grünenthal for the development and commercialization of cell therapy solutions for chronic low back pain. Mesoblast Limited was established in 2004 and maintains its headquarters in Melbourne, Australia.
Fri, 11 Sep 2026
Mesoblast Stock Price Forecast. Should You Buy MESO? - StockInvest.us
Sun, 06 Sep 2026
How Mesoblast Limited (MESO) Affects Rotational Strategy Timing - Stock Traders Daily
Tue, 25 Aug 2026
Mesoblast (NASDAQ: MESO) gives director 875,000 incentive options - Stock Titan
Wed, 12 Aug 2026
Mesoblast Limited 2026 Q4 - Results - Earnings Call Presentation (NASDAQ:MESO) 2026-08-12 - Seeking Alpha
Tue, 28 Jul 2026
Mesoblast Limited (MESO) Stock Analysis: Unlocking A 140% Upside Potential For Investors - DirectorsTalk Interviews
Fri, 17 Jul 2026
Mesoblast Limited (MESO) is a Great Momentum Stock: Should You Buy? - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 130 (M) |
| Shares Float | 84 (M) |
| Held by Insiders | 5.8 (%) |
| Held by Institutions | 3.2 (%) |
| Shares Short | 3,010 (K) |
| Shares Short P.Month | 3,130 (K) |
| EPS | -0.44 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 4.38 |
| Profit Margin | -47.9 % |
| Operating Margin | -33.3 % |
| Return on Assets (ttm) | -4.2 % |
| Return on Equity (ttm) | -9.9 % |
| Qtrly Rev. Growth | 390.7 % |
| Gross Profit (p.s.) | 0.74 |
| Sales Per Share | 0.92 |
| EBITDA (p.s.) | -0.35 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -44 (M) |
| Levered Free Cash Flow | -52 (M) |
| PE Ratio | -34.14 |
| PEG Ratio | 0 |
| Price to Book value | 3.42 |
| Price to Sales | 16.21 |
| Price to Cash Flow | -44.5 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|